7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,592.02

+550.63

+0.71%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Delayed Quote USD

Phio Pharmaceuticals Corp. (PHIO)

0.8600 -0.0026 (-0.30%)

At close: October 30 at 4:00:01 PM EDT

Loading Chart for PHIO

Chart Range Bar

Interval:

In partnership with ChartIQ

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026

Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026

Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference

Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference

Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones

Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones

Mobilize your Website

View Site in Mobile | Classic

Share by: